Kara Elam is currently working on her Doctorate in Health Policy. She holds Master Degrees in both epidemiology and microbiology. Her research interests include emerging viral diseases, the intersection of human rights and intellectual property rights, and ending violence against women.
Multiple sclerosis (MS) patients who used the RebiSmart (Merck Serono) device to inject themselves with interferon beta-1a (INF β-1a) did an excellent job of sticking to their treatment timetable without ... Read more
Researchers from Oryzon will present efficacy data on the company’s oral epigenetic drug ORY-2001, a potential treatment for multiple sclerosis (MS), at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress ... Read more
Biogen, a global biotechnology company with over 30 years of clinical excellence in Multiple Sclerosis (MS) research, has recently announced the launch of Reimagine MySelf, a blog dedicated to ... Read more
This week, Belgian-based biopharmaceutical company Ablynx announced they have entered into an exclusive research collaboration with Genzyme, a Sanofi company, to investigate the use of Nanobodies as part of ... Read more
This week the Consortium of Multiple Sclerosis Centers (CMSC) in collaboration with The France Foundation, a provider of continuing medical education have launched a new educational program focused on ... Read more
A study published by a team of investigators at the University of Tokyo’s Institute of Medical Science and Osaka University’s Graduate School of Engineering presented new evidence demonstrating how Toll-like receptor ... Read more